BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Back in November 2023, I published a note on BioCryst (NASDAQ: BCRX ) to Seeking Alpha, assigning its stock a "Sell" rating. At the time, shares were priced at $5.5, and in ...